DelveInsight’s Aspergillosis Market Insights report provides a thorough understanding of current treatment practices, emerging drugs, Aspergillosis market share of the individual therapies, current and forecasted Aspergillosis market size from 2019 to 2032 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).
Aspergillosis Overview
Aspergillosis is an infection or allergic reaction that is caused by the aspergillus fungus, which is commonly found in the environment. Aspergillus is a ubiquitous fungus that causes a variety of clinical syndromes. Exposure to Aspergillus conidia through inhalation is common, however, only a minority of those exposed will develop lung disease. People with weakened immune systems or lung diseases are at a higher risk of developing health problems due to aspergillus.
Download Sample Report @ Aspergillosis Market
Some of the key features of the Aspergillosis Market Report
- According to DelveInsight’s analysis, among the types of Aspergillosis, ABPA patient pool highest mainly due to occurrence in larger population of Asthma and Cystic fibrosis.
- As per the DelveInsight’s analysis, the diagnosed and treated cases of ABPA, IA and CPA was found to be 1,124,997, 37,528, and 23,831 respectively in 2019 in the 7MM.
- The total Aspergillosisprevalent population of three major subtypes. i.e., ABPA, IA and CPA was around 546,697 in the United States (in 2018). The diagnosis rate is highest for IA (i.e., more severe from compared to ABPA and CPA), followed by expected similar rate for ABPA and CPA.
- Aspergillosis companies such as Astellas Pharma/ Basilea Pharmaceutica International, F2G, Scynexis, Pulmocide, and several others.
- Aspergillosis therapies such as Cresemba, Olorofim (F901318), Voriconazole Inhalation (ZP-059), Voriconazole dry-powder inhalation (TFF-VORI), Ibrexafungerp, PC945, Pulmazole (PUR1900), and several others.
- Fever
- Chest pain
- Cough
- Coughing up blood
- Shortness of breath
- Several others
Aspergillosis Types
- Chronic pulmonary aspergillosis (CPA),
- Invasive aspergillosis (IA)
- Allergic bronchopulmonary aspergillosis (ABPA).
The treatment of aspergillosis varies according to the type of aspergillosis present, the extent of the infection, an individual’s overall health, and other factors. The current treatment is mainly based on the use of traditional antifungal medications like azoles (voriconazole, Itraconazole, and isavuconazole and others), antibiotics, corticosteroids and surgery (may be used in case of invasive aspergillosis). The current treatment of aspergillosis is mainly done by using traditional antifungal therapies, however, the drug-like Cresemba is also used in the treatment of specific types of aspergillosis like IA. In case ABPA, steroids are also used with antifungal agents, on the other hand in case of CPA traditional antifungal agents are only available treatment.
Get an overview of the report @ Aspergillosis Market Report
Aspergillosis Epidemiology Segmentation
- Prevalent Cases by types
- Diagnosed and treated pool by types
Aspergillosis Market Insights
Aspergillosis is an infection caused by Aspergillus, a common mold (a type of fungus) that lives indoors and outdoors. Most people breathe in Aspergillus spores every day without getting sick. However, people with weakened immune systems or lung diseases are at a higher risk of developing health problems due to Aspergillus. The types of health problems caused by Aspergillus include allergic reactions, lung infections, and infections in other organs. General surgery cases only account for 2% of these, with the majority occurring in cardiac, transplant, ophthalmologic, or burn patients.
Aspergillosis Treatment Market
To accomplish and meet these unmet needs the future of Aspergillosis treatment is continuing to incline toward extended therapies as well as more novel approaches. In terms of future competition, additional products are coming to market as well as other new technologies.
Aspergillosis Emerging Therapy Assessment
The available therapeutics treatment options in Aspergillosis Landscape aim to reduce the fungal infections in patients. Scynexis is developing the first representative, a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids known as Ibrexafungerp (formerly known as SCY-078). It has shown activity against Aspergillus, Candida and multidrug-resistant (MDR) species. Ibrexafungerp combines the well-established activity of glucan synthase inhibitors with the flexibility of oral and IV formulations, offering broad use across different settings (in-patient and out-patient). It has the potential to be an essential therapy in the treatment of multiple serious fungal infections, including Vulvovaginal Candidiasis (VVC), invasive candidiasis, Invasive Aspergillosis (IA) and refractory invasive fungal infections.
Aspergillosis Market Drivers
- Research and development strategies
- Increasing Burden of various forms of Aspergillosis
Aspergillosis Market Barriers
- Availability of generics and off-label therapies
- Lack of accurate diagnosis
Aspergillosis Market Report Scope
- Study Period- 2019-2032
- Coverage- The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan
- Key Companies: Astellas Pharma/ Basilea Pharmaceutica International, F2G, Scynexis, Pulmocide, and several others.
- Key Therapies: Cresemba, Olorofim (F901318), Voriconazole Inhalation (ZP-059), Voriconazole dry-powder inhalation (TFF-VORI), Ibrexafungerp, PC945, Pulmazole (PUR1900), and several others.
- Unmet Needs
- KOL’s Views
- Market Drivers
- Market Barriers
Request Sample Report @ Aspergillosis Market Outlook
Table of Content
1. Key Insights
2. Executive Summary of Aspergillosis
3. Competitive Intelligence Analysis for Aspergillosis
4. Aspergillosis: Market Overview at a Glance
5. Aspergillosis: Disease Background and Overview
6. Patient Journey
7. Aspergillosis Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Aspergillosis Unmet Needs
10. Key Endpoints of Aspergillosis Treatment
11. Aspergillosis Marketed Products
12. Aspergillosis Emerging Therapies
13. Aspergillosis: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Aspergillosis
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash
info@delveinsight.com
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/